Physician profile
Ritchie Rosso
NPI 1669629101
$24,262.40
in general payments reported to CMS, 2019-2025
37 companies · $3,668 in 2025
The $3,668 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,273 · 2020: $2,642 · 2021: $2,859 · 2022: $3,178 · 2023: $4,385 · 2024: $4,258 · 2025: $3,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,212.27 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,297.43 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Sun Pharmaceutical Industries INC. | $2,745.33 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $1,957.18 | 2019-2025 | |
| Amgen INC. | $1,805.27 | 2019-2025 | Otezla, Otezla, Enbrel |
| Lilly USA, LLC | $1,490.60 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,389.75 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $1,353.59 | 2019-2025 | Tremfya, Stelara, Simponi |
| Arcutis Biotherapeutics, INC. | $1,138.13 | 2023-2025 | Zoryve |
| Ucb, INC. | $1,120.82 | 2022-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $1,075.22 | 2019-2025 | |
| Genzyme Corporation | $1,069.69 | 2019-2025 | |
| Leo Pharma INC. | $563.22 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $553.96 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Allergan, INC. | $548.23 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $511.85 | 2022-2025 | Sotyktu |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $476.01 | 2019-2024 | Cabtreo, Arazlo |
| Incyte Corporation | $373.04 | 2022-2025 | Opzelura |
| Celgene Corporation | $288.65 | 2019 | |
| Vyne Pharmaceuticals INC. | $224.55 | 2020 | |
| Merz North America, INC. | $214.79 | 2019-2024 | |
| Organon LLC | $150.97 | 2025 | Vtama |
| Pfizer INC. | $144.59 | 2019-2021 | |
| Almirall LLC | $106.75 | 2019-2022 | |
| Biofrontera INC. | $104.36 | 2020-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $95.08 | 2019-2024 | Xolair |
| Strata Skin Sciences, INC. | $83.50 | 2024 | Xtrac |
| Dermira, INC. | $67.98 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $64.43 | 2019 | |
| Dusa Pharmaceuticals, INC. | $53.59 | 2019 | |
| Lumenis, INC | $53.31 | 2021 | |
| Kerecis Limited | $37.10 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Dermavant Sciences, INC. | $27.35 | 2023 | Vtama |
| Aclaris Therapeutics, INC. | $19.44 | 2019 | |
| Organogenesis INC. | $16.40 | 2020 | |
| Mission Pharmacal Company | $13.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.42 | 2023 | Spevigo |
| Prugen, INC. Pharmaceuticals | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritchie Rosso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.